AbbVie Reports Third-Quarter 2026 Financial Results
AbbVie reported third-quarter 2026 net revenue of US$17.4b and basic earnings per share of US$2.38, beating estimates and prompting the company to lift its full-year revenue and adjusted earnings guidance. Growth was driven primarily by the company's neuroscience and immunology portfolios, specifically the performance of Skyrizi and Rinvoq. While the stock reached an all-time high and rose to approximately US$294.83 following the release, some reports indicate the stock also experienced a dip despite the positive earnings print. GAAP diluted EPS rose over 100.0 percent to $2.37, while adjusted diluted EPS increased over 100.0 percent to $3.82.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ AbbVie reported third-quarter net revenue of US$17.4b.
- ✓ Basic earnings per share for the third quarter were US$2.38.
- ✓ The company increased its 2026 revenue and earnings outlook.
- ✓ Growth in the third quarter was fueled by immunology and neuroscience drugs, specifically Skyrizi and Rinvoq.
What changed
AbbVie released its third-quarter 2026 financial results and increased its annual profit and revenue outlook.
Live updates
-
AbbVie Raises 2026 Forecast Following Strong Third-Quarter Results
AbbVie reported third-quarter 2026 net revenue of US$17.4b and basic earnings per share of US$2.38, beating estimates and prompting the company to lift its full-year revenue and adjusted earnings guidance. Growth was driven primarily by the company's neuroscience and immunology portfolios, specifically the performance of Skyrizi and Rinvoq. While the stock reached an all-time high and rose to approximately US$294.83 following the release, some reports indicate the stock also experienced a dip despite the positive earnings print. GAAP diluted EPS rose over 100.0 percent to $2.37, while adjusted diluted EPS increased over 100.0 percent to $3.82.
Why it matters
The company is transitioning its growth drivers as immunology and neuroscience drugs replace older revenue streams. Investors are closely monitoring whether the current momentum in the pipeline can sustain the company's high valuation.
What is confirmed
- AbbVie reported third-quarter net revenue of US$17.4b.
- Basic earnings per share for the third quarter were US$2.38.
- The company increased its 2026 revenue and earnings outlook.
- Growth in the third quarter was fueled by immunology and neuroscience drugs, specifically Skyrizi and Rinvoq.
- GAAP diluted EPS was $2.37, an increase of over 100.0 percent.
- Adjusted diluted EPS was $3.82, an increase of over 100.0 percent.
Still unconfirmed
- AbbVie stock dipped despite beating estimates.
- AbbVie stock rose 3.1% to about US$294.83 after the release.
What to watch next
- Updates on oncology pipeline milestones
- Future quarterly reports to verify if raised 2026 guidance is met
confidence 95%Sources used for this update (19)
- AbbVie News Center — AbbVie Reports Third-Quarter 2026 Financial Results
- Reuters — AbbVie lifts annual profit forecast as immunology drugs continue to fuel growth
- WSJ — AbbVie Revenue Rises on Strength in Immunology, Neuroscience
- Yahoo Finance — Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings
- TradingView — LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today
- Fierce Pharma — As Skyrizi and Rinvoq dominate AbbVie's Q3, analysts ask what's next
- Yahoo Finance — AbbVie beats estimates but stock dips
- www.aol.com — Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- finance.yahoo.com — ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
- 247wallst.com — 2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
- 247wallst.com — 4 Elite Dividend Stocks That Pay You Passive Income Every Quarter
- www.prnewswire.com — AbbVie Reports Third-Quarter 2026 Financial Results - PR Newswire
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community